Market Intelligence, Clinical Progress, and High-Purity Reagents for Galectin-7-Targeted Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LGALS7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALS7 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View LGALS7 Products |
| Gene Delivery | LGALS7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LGALS7 Products |
| Benchmark Ab | Anti-LGALS7 Recombinant Antibody Recombinant positive control. |
View LGALS7 Products |
| Validator | LGALS7 siRNA Set For knockdown verification. |
View LGALS7 Products |
| Related Target A | LGALS1 (Galectin-1) Synergistic immunomodulation and off-target selectivity screening. |
View LGALS1 Products |
| Related Target B | LGALS3 (Galectin-3) Critical family member for counter-screening to prevent cross-reactivity. |
View LGALS3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling across the highly conserved Galectin family | Homolog panel proteins (LGALS1, LGALS3, LGALS7) strictly verified by mass spectrometry and high-purity chromatography (>95% purity) |
| Evaluating dimerization-disrupting inhibitors | Sequence-verified wild-type and monomeric-designed recombinant proteins available for precise biophysical assays (SPR/MST) |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live LGALS7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGALS7 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum galectin inhibitors to highly selective monoclonal antibodies and targeted small molecules. As first-generation pan-galectin therapies reach the clinic, the next wave of R&D is targeting LGALS7 specifically due to its restricted expression in stratified squamous epithelium, offering a safer therapeutic window for squamous cell carcinomas (esophageal, cervical, head and neck) and inflammatory skin disorders like psoriasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biotech Startups, Academic Consortia | Esophageal Squamous Cell Carcinoma, Psoriasis | Epitope mapping & ligand blocking assays (Need high-purity, low-endotoxin LGALS7 ECD-Fc) |
| Small Molecule Inhibitors | Specialized Glycobiology Pharma | Epithelial Cancers, Fibrotic Disorders | Selectivity assay vs LGALS1/3 (Need Mutant vs WT Galectin recombinant protein panels) |
| siRNA Therapeutics | RNAi Biotechs | Squamous Cell Carcinomas | In vitro knockdown validation & target engagement (Need LGALS7 siRNA & Lentivirus) |